Sutent + Taxol for Advanced Esophageal Cancer
Public ClinicalTrials.gov record NCT00730353. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase II Study of Sunitinib Malate (Sutent®) With Paclitaxel (Taxol®) in Patients With Advanced Esophageal Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Paclitaxel is known to be active as a single and combination agent in esophageal cancer, and has also been demonstrated to have anti-angiogenic properties in weekly dosing regimens. Sunitinib malate is an anti-angiogenic drug with the potential to improve responses when combined with chemotherapy, as demonstrated with other regimens in similar settings. We believe that the combination of paclitaxel and sunitinib malate offer great promise in the treatment of advanced esophageal cancer.
Study identification
- NCT ID
- NCT00730353
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 28 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 2008 (Type not available)
- Primary completion
- Mar 2010 (Actual)
- Completion
- Mar 2010 (Actual)
- Last update posted
- Mar 16, 2017
2008 – 2010
United States locations
- U.S. sites
- 15
- U.S. states
- 3
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Northwestern University Feinberg School of Medicine | Chicago | Illinois | 60611 | — |
| Rush-Presbyterian St. Luke's Medical Center | Chicago | Illinois | 60612 | — |
| Medical & Surgical Specialists, LLC | Galesburg | Illinois | 61401 | — |
| Cancer Care Center of Southern Indiana | Bloomington | Indiana | 47403 | — |
| Oncology Hematology Associates of SW Indiana | Evansville | Indiana | 47714 | — |
| Fort Wayne Oncology & Hematology, Inc | Fort Wayne | Indiana | 46815 | — |
| IN Onc/Hem Associates | Indianapolis | Indiana | 46202 | — |
| Indiana University Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Arnett Cancer Care | Lafayette | Indiana | 47904 | — |
| Horizon Oncology Center | Lafayette | Indiana | 47905 | — |
| Medical Consultants, P.C. | Muncie | Indiana | 47303 | — |
| Monroe Medical Associates | Munster | Indiana | 46321 | — |
| Northern Indiana Cancer Research Consortium | South Bend | Indiana | 46601 | — |
| Providence Medical Group | Terre Haute | Indiana | 47802 | — |
| Ireland Cancer Center - University Hospitals of Cleveland | Cleveland | Ohio | 44106 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00730353, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 16, 2017 · Synced Nov 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00730353 live on ClinicalTrials.gov.